Standard BioTools Divests Microfluidics Business to ARCHIMED
LAB sits 22% above its 52-week low of $0.625.
Summary
A definitive agreement has been reached to sell the Microfluidics business to ARCHIMED, with closing expected in approximately 30 days. Financial terms were not disclosed.
Key Events · M&A and Partnerships · LAB
-
Microfluidics Business Sold to ARCHIMED
A definitive agreement has been signed to sell the Microfluidics business to ARCHIMED, a healthcare-focused investment firm.
-
Closing Expected in ~30 Days
The transaction is expected to close in approximately 30 days, subject to customary closing conditions.
-
Financial Terms Not Disclosed
The purchase price and other financial terms of the Microfluidics sale were not disclosed in the filing.
-
Part of Ongoing Divestiture Strategy
This sale follows the recent divestiture of the Mass Cytometry business to Element Biosystems for $5.5 million, as the company streamlines operations ahead of its pending reverse merger with Treeline Biosciences.
Analysis · LAB · Life Sciences
The strategic divestiture program continues with an agreement to sell the Microfluidics business to ARCHIMED, a healthcare-focused investment firm. Closing is anticipated in about 30 days, subject to customary conditions. While the undisclosed purchase price limits assessment of the financial impact, this sale marks another step in the company's restructuring ahead of its pending reverse merger with Treeline Biosciences.
How filings like this one have moved
In the 30 days to Oct 5, 2026, 29.2% of the 1496 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.63%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, LAB was trading at $0.76 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $299.5M. The 52-week trading range was $0.63 to $1.72. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.